RCUS logo

Arcus Biosciences (RCUS)

Profile

Full Name

Arcus Biosciences, Inc.

Ticker Symbol

RCUS

Exchange

NYSE

Country

United States

IPO

March 15, 2018

Indexes

Not included

Employees

627

Key Details

Price

$7.86(+11.65%)

Market cap

$831.91M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$258.00M(+120.51% YoY)

Annual EPS

-$3.14(+24.34% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Feb 26, 25 HC Wainwright & Co.
Buy
Feb 19, 25 B of A Securities
Neutral
Feb 18, 25 Morgan Stanley
Overweight
Feb 18, 25 HC Wainwright & Co.
Neutral
Nov 6, 24 HC Wainwright & Co.
Neutral
Oct 25, 24 Barclays
Overweight
Oct 24, 24 HC Wainwright & Co.
Neutral
Oct 21, 24 HC Wainwright & Co.
Neutral
Oct 8, 24 Wells Fargo
Overweight
Oct 7, 24 Cantor Fitzgerald
Overweight

Institutional Ownership

  • What is the ticker symbol for Arcus Biosciences?
  • Does Arcus Biosciences pay dividends?
  • What sector is Arcus Biosciences in?
  • What industry is Arcus Biosciences in?
  • What country is Arcus Biosciences based in?
  • When did Arcus Biosciences go public?
  • Is Arcus Biosciences in the S&P 500?
  • Is Arcus Biosciences in the NASDAQ 100?
  • Is Arcus Biosciences in the Dow Jones?
  • When was Arcus Biosciences's last earnings report?
  • When does Arcus Biosciences report earnings?
  • Should I buy Arcus Biosciences stock now?

What is the ticker symbol for Arcus Biosciences?

The ticker symbol for Arcus Biosciences is NYSE:RCUS

Does Arcus Biosciences pay dividends?

No, Arcus Biosciences does not pay dividends

What sector is Arcus Biosciences in?

Arcus Biosciences is in the Healthcare sector

What industry is Arcus Biosciences in?

Arcus Biosciences is in the Biotechnology industry

What country is Arcus Biosciences based in?

Arcus Biosciences is headquartered in United States

When did Arcus Biosciences go public?

Arcus Biosciences's initial public offering (IPO) was on March 15, 2018

Is Arcus Biosciences in the S&P 500?

No, Arcus Biosciences is not included in the S&P 500 index

Is Arcus Biosciences in the NASDAQ 100?

No, Arcus Biosciences is not included in the NASDAQ 100 index

Is Arcus Biosciences in the Dow Jones?

No, Arcus Biosciences is not included in the Dow Jones index

When was Arcus Biosciences's last earnings report?

Arcus Biosciences's most recent earnings report was on Feb 25, 2025

When does Arcus Biosciences report earnings?

The next expected earnings date for Arcus Biosciences is May 8, 2025

Should I buy Arcus Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page